FTSE 100 Live: London index flat as oil, tobacco and defence offset wider losses
London’s FTSE 100 was flat to slightly higher, up 3 points to 10,371, as rising oil prices on Iran-Israel airstrikes and gains in tobacco and defence offset wider losses. In Europe, Tate & Lyle rose nearly 15% after agreeing to be taken over. Zealand Pharma fell 23% after Boehringer Ingelheim reported side effects in an obesity drug trial. The FCA launched civil proceedings against Neil Woodford and W4.0.
AMD’s UK capex/infrastructure plan is a positive, concrete expansion signal for its compute and sovereign-AI strategy.
AMD announced £2B of UK investments over five years, including a nuclear-fusion supercomputer project at Cambridge.
Mild positive sentiment; likely limited immediate price impact unless investors extrapolate material near-term revenue.
Background
The piece is a London/Europe market wrap tied to Iran-Israel airstrike headlines, oil moves, and shifting US rate expectations, with several company-specific items embedded (Zealand Pharma/partner trial, FCA action, and select corporate announcements).
Why it matters
Near-term trading focus is on (1) Zealand Pharma’s sharp repricing tied to a partner’s late-stage obesity-drug side-effect signal, and (2) sector momentum in semiconductors after Friday’s sell-off, plus (3) index-level rotation in FTSE defensives as oil and rates swing intraday.
Market relevance
This is primarily a market wrap, but it contains actionable single-name catalysts (Zealand Pharma’s partner trial safety disclosure; FCA enforcement; AMD capex announcement; Marvell index inclusion).
Market effects
Geopolitics-driven oil volatility and rate expectations are driving index-level rotation; semis rebound is sentiment/positioning-led.
London’s defensive FTSE leadership contrasts with weaker DAX performance; Euro Stoxx 600 near flat.
Iran-Israel headline flow is influencing oil and global risk appetite; US semiconductor volatility is spilling into European tech sentiment.
Alternative perspectives
The US semiconductor rebound may be a short-covering/positioning bounce rather than a durable fundamental turn, limiting follow-through for European tech.
The article’s key single-name shock is Zealand Pharma’s partner trial safety disclosure; traders may be underweighting how quickly partner data can reprice obesity-drug probabilities.
Key entities
- companyZealand Pharma
FTSE/Europe loser: shares plunge 23% after partner Boehringer Ingelheim reports late-stage obesity-drug side effects.
- companyBoehringer Ingelheim
Partner discloses late-stage trial safety outcome that triggers the Zealand Pharma selloff.
- regulatorFCA
Launches civil proceedings against Neil Woodford and W4.0 alleging unauthorized regulated investment advice/promotions.
- companyAMD
Announces £2B UK investment plan including a nuclear-fusion supercomputer project at Cambridge.
- companyUber
Deal pursuit context: FT reports a Saudi startup may bid for Delivery Hero’s Middle East assets.
